Incretin Atlas › Molecules › Macupatide
Macupatide
GIP · s.c. · Eli Lilly
Summary
- Also known as
- LY3532226, Eli Lilly
- Mechanism
- GIP
- Route
- s.c.
- Company
- Eli Lilly
- Highest development stage
- phase 2
- Status (as of data cut)
- Phase 2 (alone and with eloralintide) verify
- Next milestone
- Phase 2 results
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 1 phase 2 / signal | Phase 2, alone and with eloralintide | Macupatide ± eloralintide phase 2 |
| T2D | 0 no data | ||
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
No trial arms with extracted efficacy or tolerability data yet.
Primary sources
No source recorded.
How to cite this page
Medical Adviser's Group. Incretin Atlas: Macupatide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/macupatide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.